Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Revolution Medicines Inc is a biotechnology business based in the US. Revolution Medicines shares (RVMD) are listed on the NASDAQ and all prices are listed in US Dollars. Revolution Medicines employs 150 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$27.30|
|52-week range||$24.38 - $56.18|
|50-day moving average||$29.06|
|200-day moving average||$31.30|
|Wall St. target price||$33.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.08|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||-2.50%|
|1 month (2021-09-24)||-11.10%|
|3 months (2021-07-23)||-5.67%|
|6 months (2021-04-23)||-33.74%|
|1 year (2020-10-23)||-32.38%|
|2 years (2019-10-21)||N/A|
|3 years (2018-10-21)||N/A|
|5 years (2016-10-21)||N/A|
|Revenue TTM||$40.2 million|
|Gross profit TTM||$-89,269,000|
|Return on assets TTM||-14.61%|
|Return on equity TTM||-27.34%|
|Market capitalisation||$2 billion|
TTM: trailing 12 months
There are currently 10.3 million Revolution Medicines shares held short by investors – that's known as Revolution Medicines's "short interest". This figure is 4.4% up from 9.9 million last month.
There are a few different ways that this level of interest in shorting Revolution Medicines shares can be evaluated.
Revolution Medicines's "short interest ratio" (SIR) is the quantity of Revolution Medicines shares currently shorted divided by the average quantity of Revolution Medicines shares traded daily (recently around 482907.12611346). Revolution Medicines's SIR currently stands at 21.33. In other words for every 100,000 Revolution Medicines shares traded daily on the market, roughly 21330 shares are currently held short.
However Revolution Medicines's short interest can also be evaluated against the total number of Revolution Medicines shares, or, against the total number of tradable Revolution Medicines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Revolution Medicines's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Revolution Medicines shares in existence, roughly 140 shares are currently held short) or 0.2075% of the tradable shares (for every 100,000 tradable Revolution Medicines shares, roughly 208 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Revolution Medicines.
Find out more about how you can short Revolution Medicines stock.
We're not expecting Revolution Medicines to pay a dividend over the next 12 months.
Revolution Medicines, Inc. , a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.